Mahri Park

Mahri Park

Auto-generated profile, based on publicly available information

Mahri Park

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
ACAndrew James Counsell
Andrew James Counsell
SWStephen J. Walsh
Stephen J. Walsh
NANicola Ashman
Nicola Ashman
MPMahri Park
Mahri Park
FDFriederike M. Dannheim
Friederike M. Dannheim
DSDavid Spring
David Spring
Herein we report the development of a novel linker platform for tumour-responsive antibody–drug conjugates.

12 June 2024 in Chemical Communications
Verified
Journal Article
Open access
PDF file
RWRaoul Walther
Raoul Walther
MPMahri Park
Mahri Park
NANicola Ashman
Nicola Ashman
MWMartin Welch
Martin Welch
JCJason S. Carroll
Jason S. Carroll
DSDavid Spring
David Spring
We describe a versatile and tuneable thiol responsive linker system using thiovinylketones, that relies on the conjugate addition–elimination mechanism of Michael acceptors for the traceless release of therapeutics.

29 May 2026 in Chemical Science
Verified
Journal Article
Open access
PDF file
MPMahri Park
Mahri Park
FDFriederike M. Dannheim
Friederike M. Dannheim
MPMonika A. Papworth
Monika A. Papworth
RKRichard Kay
Richard Kay
ETElpida Tsonou
Elpida Tsonou
DSDavid Spring
David Spring
Herein, we report a semi-synthetic strategy for generating Fc–peptide conjugates via disulfide re-bridging linker bioconjugation that retained biological activity in vitro and exhibited prolonged circulation in vivo .

28 October 2025 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MKMia Kapun
Mia Kapun
RPRoshan Patel
Roshan Patel
MPMahri Park
Mahri Park
FLF. Javier Luque
F. Javier Luque
KKKristina A. Kostadinova
Kristina A. Kostadinova
DSDavid Spring
David Spring
Herein we describe the development of a novel azobenzene-containing glutathione-cleavable linker for use in antibody–drug conjugates (ADCs).